Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery.
Squamous cell carcinoma of the hypopharynx represents a distinct clinical entity. Most patients present with significant comorbidities and advanced-stage disease. The overall survival is relatively poor because of high rates of regional and distant metastasis at presentation or early in the course of the disease. A multidisciplinary approach is crucial in the overall management of these patients to achieve the best results and maintain or improve functional results. Traditionally, operable hypopharyngeal cancer has been treated by total (occasionally partial) laryngectomy and partial or circumferential pharyngectomy, followed by reconstruction and postoperative radiotherapy in most cases. Efforts to preserve speech and swallowing function in the surgical treatment of hypopharyngeal (and laryngeal) cancer have resulted in a declining use of total laryngopharyngectomy and improved reconstructive efforts, including microvascular free tissue transfer. There are many surgical, as well as nonsurgical, options available for organ and function preservation, which report equally effective tumor control and survival. The selection of appropriate treatment is of crucial importance in the achievement of optimal results for these patients. In this article, several aspects of surgical and nonsurgical approaches in the treatment of hypopharyngeal cancer are discussed. Future studies must be carefully designed within clearly defined populations and use uniform terminology and standardized functional assessment and declare appropriate patient or disease endpoints. These studies should focus on improvement of results, without increasing patient morbidity. In this respect, technical improvements in radiotherapy such as intensity-modulated radiotherapy, advances in supportive care, and incorporation of newer systemic agents such as targeted therapy, are relevant developments.
Department of Otolaryngology-Head and Neck Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Robert P
RP
Takes
Primož
P
Strojan
Carl E
CE
Silver
Patrick J
PJ
Bradley
Missak
M
Haigentz
Gregory T
GT
Wolf
Ashok R
AR
Shaha
Dana M
DM
Hartl
Jan
J
Olofsson
Johannes A
JA
Langendijk
Alessandra
A
Rinaldo
Alfio
A
Ferlito
D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D059248:Chemoradiotherapy; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D007013:Hypopharynx / Q000601:surgery; D007825:Laryngectomy; D008197:Lymph Node Excision; D019060:Minimally Invasive Surgical Procedures; D009362:Neoplasm Metastasis; D010611:Pharyngectomy; D050397:Radiotherapy, Intensity-Modulated; D019651:Plastic Surgery Procedures; D000077195:Squamous Cell Carcinoma of Head and Neck; D016896:Treatment Outcome